Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.300 +0.050 (+0.80%)
Streaming Delayed Price Updated: 3:51 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans ↗
Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest. 
Via Benzinga
News headline image
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive ↗
Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis. 
Via Stocktwits
Topics Workforce
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Looking Into Kezar Life Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Kezar Narrows Loss 37 Percent in Q2 ↗
Via The Motley Fool
News headline image
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study ↗
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review. 
Via Benzinga
News headline image
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate ↗
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use. 
Via Benzinga
News headline image
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study ↗
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths ↗
Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug ↗
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases. 
Via Benzinga
News headline image
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024 ↗
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024 ↗
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires ↗
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries. 
Via InvestorPlace
News headline image
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026 ↗
Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology. 
Via InvestorPlace
News headline image
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023 ↗
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
News headline image
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond ↗
When you want to light your afterburners, these ideas will do the trick. 
Via InvestorPlace
News headline image
3 Penny Stocks Poised for an Unbelievable 1,000% Jump ↗
Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await. 
Via InvestorPlace
News headline image
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits ↗
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining. 
Via Benzinga
Topics Initial Public Offering
News headline image
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth ↗
Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.